Affiliation of authors: Department of Thoracic/Head and Neck Medical Oncology (J-YH, SHO, FM, EK, WKH, H-OL), Department of Head and Neck Surgery (JNM), The University of Texas M. D. Anderson Cancer Center, Houston, TX
Correspondence to: Ho-Young Lee, PhD, Unit 432, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 (e-mail: hlee{at}mdanderson.org).
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Among various proteins that have been identified as potential targets of antiangiogenesis therapy is vascular endothelial cell growth factor (VEGF). VEGF is expressed by activated endothelial cells and promotes the proliferation, survival, and migration of endothelial cells, and thus it is essential for blood vessel formation (4). In addition, the expression and secretion of VEGF by tumor cells are stimulated by activation of Ras (5) and the phosphatidylinositol 3-kinase (PI3K)Akt pathway (6,7). The major physiologic stimulus for VEGF expression is hypoxia, which induces transcription of the VEGF gene by hypoxia-inducible factor 1 (HIF-1). HIF-1 is a heterodimer composed of HIF-1 and HIF-1
subunits (1,8). A nuclear localization signal at the carboxyl-terminal end of HIF-1
allows its transport from the cytoplasm to the nucleus, where it forms an active transcription complex by binding to HIF-1
. HIF-1
is constitutively expressed, whereas the expression and activity of HIF-1
protein are regulated by O2-dependent and -independent mechanisms [for review, see Harris (9)]. Under normoxic conditions, HIF-1
is subject to O2-dependent prolyl hydroxylation, which triggers binding of von HippelLindau tumor suppressor protein (VHL) and ubiquitin-mediated protein degradation by proteasome (10,11). Under the hypoxic condition, O2 becomes limiting for prolyl hydroxylase activity, HIF-1
ubiquitination is inhibited, and active HIF-1 transcription complexes can be formed. However, the level of HIF-1
also increases via an O2-independent mechanism (6,7). Growth factors, such as epidermal growth factor, heregulin, insulin-like growth factors (IGFs) I and -II, and insulin, induce expression of HIF-1
protein under nonhypoxic conditions (7,12,13). They bind to cognate receptor tyrosine kinases and activate the PI3K or mitogen-activated protein kinase (MAPK) pathway, which in turn increases the rate of HIF-1
protein synthesis. PI3KAkt and MAPK have also been implicated in the stabilization of HIF-1
induced by oncogenes, hypoxia, and growth factors [for review, see Semenza (14)]. HIF-1 associates with the molecular chaperone heat shock protein 90 (Hsp90); pharmacologic disruption of this association promotes the ubiquitination and proteasome-mediated degradation of HIF-1 in an oxygen- and VHL-independent manner (15), suggesting that inhibitors of the interaction between HIF-1
and Hsp90 could be used to regulate the expression of hypoxia- or IGF-Iinduced HIF-1
protein.
We have shown that SCH66336, a nonpeptide tricyclic farnesyltransferase inhibitor (FTI) that inhibits the farnesylation of various components, in combination with other inhibitors of the receptor tyrosine kinase signaling pathway, inhibits the growth of nonsmall-cell lung cancer (NSCLC) cells (16). In addition, in this study, we found that treatment with SCH66336 alone led to regression of orthotopic tongue tumors of human head and neck squamous cell carcinoma (HNSCC) in mice. Because angiogenesis is an essential step in the transition of a tumor from a small cluster of mutated cells to a large, malignant growth (17), we investigated the activity of SCH66336 on VEGF and HIF-1 expression and the mechanisms of its antiangiogenic action in aerodigestive tract cancers.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
UMSCC38 HNSCC cells established originally by Dr. Thomas Carey (University of Michigan, Ann Arbor) were obtained from Dr. Reuben Lotan (18). We purchased the human NSCLC cell line H1299 from American Type Culture Collection (Manassas, VA). These cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and antibiotics. Human umbilical vein endothelial cells (HUVECs; Cambrex BioScience, Walkersville, MD) were maintained in a gelatin-coated dish in endothelial growth medium (Cambrex BioScience) at 37 °C in a humidified atmosphere of 5% CO295% air. HUVECs used in this study were from passages 27. Tissue culture reagents and plasticware were from Nunc (Roskilde, Denmark). Transwell chambers were from Corning-Costar (Corning, NY). Amicon Ultra-4 centrifugal filter was obtained from Millipore Co. (Bedford, MA). Cell culture inserts incorporating polyester transwell membranes (6.4-mm diameter with a 8-µm pore size) and 24-well plates were from Costar (Cambridge, MA). We used the following adenoviral (Ad) vectors for experiments in this article: a vector expressing constitutively active MAP kinase kinase (MEK) 1 (in which both serine residues at positions 217 and 221 were changed to a glutamine residue), referred to as Ad-MEK1 (19); a vector expressing constitutively active Akt (MyrAkt), referred to as Ad-HA-MyrAkt (20); a vector expressing hemagglutinin (HA)-tagged Hsp90, referred to as Ad-HA-Hsp90 (21); and an empty vector, referred to as EV. These vectors were amplified as described previously (16). Female nude mice, 6 weeks old, were purchased from Harlan-Sprague Dawley (Indianapolis, IN). SCH66336, i.e., [+]4-(2-[4-(8-chloro-3,0-dibromo-6,11-dihydro-5-benzocyclohepa(1,2-) pyridin-11-yl)-1-piperidinyl]-2-oxoethyl)-1-piperidinecarboxamide, was obtained from Schering-Plough (Kenilworth, NJ). We confirmed that SCH66336 can inhibit farnesylation (22) by assessing the level of unfarnesylated H-Ras in NSCLC cell lines after treatment with SCH66336 (data not shown). FTI-277, another farnesyltransferase inhibitor, was purchased from Calbiochem (San Diego, CA). SCH66336 and FTI-277 were dissolved in dimethyl sulfoxide at various concentrations to establish doseresponse relationships. Bovine serum albumin, gelatin, the ubiquitin inhibitors MG132 and ALLN, cycloheximide, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were obtained from Sigma-Aldrich (St. Louis, MO). Inhibitors were prepared as 20 mM stock solutions in dimethyl sulfoxide and stored at 20 °C. Synthetic small interfering RNAs (siRNAs) targeting H-ras, VHL, or HIF-1
were purchased from Ambion (Austin, TX).
Hypoxic Treatment
Tissue culture dishes were transferred to a modular incubator chamber (Billups-Rothenberg, Del Mar, CA), the chamber was sealed, and the temperature was set at 37 °C. For hypoxic exposures, cells were placed in an airtight chamber (Biospherix, Redfield, NY), the chamber was flushed with a mixture of 1% O2, 5% CO2, and 94% N2 to maintain O2 concentration at 1% with Pro-Ox model 110 O2 regulators (BioSpherix), and cells were incubated at 37 °C.
Conditioned Medium
To obtain conditioned medium from SCH66336-treated H1299 NSCLC cells, we plated 106 H1299 cells in a 10-cm-diameter plate containing RPMI 1640 medium with 10% fetal bovine serum. After 24 hours, the medium on these cells was replaced with fresh growth medium containing SCH66336 (0 or 5 µM). The plates were then incubated under normoxic or hypoxic conditions for 1 day, and cells were washed with phosphate-buffered saline, and then serum-free medium containing the same concentration of SCH66336 was added. After 2 days of incubation, conditioned medium was removed and centrifuged at 4000g for 20 minutes at 4 °C through an Amicon Ultra-4 centrifugal filter (Millipore) to remove any trace of SCH66336. The molecular mass cutoff of the filters was 5 kDa, and the molecular mass of SCH66336 (Mr = 638.6) is 0.56 kDa. The flowthrough containing excess SCH66336 was discarded, and the retentate was collected. Because SCH66336 itself may have an inhibitory effect on this assay, we confirmed that this approach efficiently removed SCH66336 from the conditioned medium by treating UMSCC38 HNSCC cells with the conditioned medium and measuring farnesylated H-ras levels in the cells by western blot analysis. We found that inhibition of H-ras farnesylation required more than 0.5 µM SCH66336 (data not shown), which was insufficient to induce antiangiogenic effects in H1299 cells. By comparing supernatants from filtration spins with that from control cells treated with known concentrations of SCH66336, we determined that the amount of SCH66336 remaining after two successive filtration spin supernatants was not sufficient to inhibit H-Ras farnesylation when the starting concentration did not exceed 10 µM. The final filter retentate was concentrated 40-fold for use in the angiogenesis assay. This conditioned medium was used for several analyses, including Matrigel plug, chick aortic arch, HUVEC proliferation, and tube formation assays.
Cell Treatments
To assess the effects of SCH66336 on the expression of various proteins and mRNAs by western blot and reverse transcriptionpolymerase chain reaction (RTPCR) analyses, we treated 106 cells per 100-mm3-diameter dish (H1299 NSCLC cells, UMSCC38 HNSCC cells, or HUVECs) with SCH66336 (0.5, 1, or 5 µM) in complete medium. For H-ras, HIF-1, VHL, or scrambled (control) siRNA transfection, H1299 cells were plated at a concentration of 105 cells per well in six-well plates. The next day, cells were transfected with 60 nmol of the indicated siRNAs by use of Oligofectamine (Invitrogen, Carlsbad, CA) for 6 hours and then cells were placed in fresh medium with or without 5 µM SCH66336. Scrambled siRNA was used as a negative control. After 2 days of incubation, medium was replaced with complete medium or serum-free medium, and then cells were incubated for another day. Serum-starved cells were stimulated by IGF-I at 100 ng/mL under normoxic (20% O2) or hypoxic (1% O2) conditions for 4 hours before harvest. Total protein extracts were collected for western blot analysis as described elsewhere (16). Briefly, cells were washed in phosphate-buffered saline and lysed in a buffer containing 50 mM TrisHCl (pH 8.0), 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, aprotinin at 5 µg/mL, and leupeptin at 5 µg/mL. After incubation on ice for 30 minutes and centrifugation at 1500g for 20 minutes at 4 °C, the supernatants were collected, and the protein concentration of each was determined with a BCA protein assay kit (Pierce, Rockford, IL).
To test the effects of SCH66336 on HIF-1 half-life, cycloheximide (100 ng/mL) was added to the medium from SCH66336-treated H1299 cells that had been stimulated with hypoxia or IGF-I for 4 hours, and whole-cell extracts were prepared as described above. In some experiments, ubiquitin inhibitors (10 µM MG132 or 10 µM ALLN) were added to growth medium when cells were stimulated with IGF-I or hypoxia.
To assess the contributions of the MAPK and Akt signaling pathways and Hsp90 expression to the SCH66336-mediated regulation of HIF-1 stability, H1299 cells were infected with Ad-HA-Myr-Akt (25 plaque-forming units [PFU] per cell), Ad-MEK (25 PFU per cell), Ad-HA-Hsp90 (50 PFU per cell), or Ad-EV (the parental virus control, 2550 PFU per cell). For infection, cells and vectors were incubated for 2 hours in the absence of serum, incubated in growth medium containing 0.55 µM SCH66336 for 2 days, and then incubated with complete medium or with serum-free medium for another day. Cells were unstimulated or stimulated by IGF-I or hypoxia for 4 hours as described above.
To test the effects of conditioned medium on proliferation of vascular endothelial cells, 3 x 103 HUVECs (in 100 µL of endothelial basal medium [EBM], Cambrex Bioscience) per well of 96-well culture plates were treated with 10 µg of conditioned medium from the hypoxic, normoxic IGF-stimulated, or unstimulated NSCLC or HNSCC cells. To test the direct effects of SCH66336 on proliferation of vascular endothelial cells, we treated 3 x 103 HUVECs per well with 1 or 5 µM SCH66336 in 96-well culture plates. After 72 hours of incubation under hypoxic or normoxic conditions, cell proliferation was assessed by the MTT assay. For each analysis, six replicate wells were used, and at least three independent experiments were performed.
Chick Aortic Arch Assay
The chick aortic arch assay was as described elsewhere (24). In brief, thoracic aortas were obtained from chick eggs after 1315 days of incubation. Excess perivascular tissue was removed, and transverse sections (12 mm) were cut. The resulting aortic rings were washed in medium 199 (Life Technologies) and embedded in 30 µL of Matrigel in 24-well plates (Costar) with the lumen perpendicular to the base of the well. Each ring was covered with 4 µL of Matrigel, which was allowed to gel, and then 300 µL of ECM and 10 µL of conditioned medium were added to each well. These plates were incubated for 24 hours or 48 hours at 37 °C to allow microvessel sprouting from the adventitial layer of the ring. The plates were photographed under a stereomicroscope (Zeiss, Göttingen, Germany), and average sprouting was measured with the imageJ program (National Institutes of Health, Bethesda, MD). Each condition was tested in six wells. The experiment was repeated three times, each with similar results.
In Vitro Capillary Tube Formation Assay
The capillary tube formation assay was as described elsewhere (23). We evenly dispersed 5 x 104 HUVECs on 250-µL Matrigel surfaces that were depleted of growth factors (Matrigel; Becton Dickinson, Bedford, MA); cells were incubated in 250 µL of EBM containing 30 µL of conditioned medium from H1299 cells cultured under hypoxic or normoxic conditions. To determine the direct effects of SCH66336 on HUVECs, cells were incubated in complete medium containing 5 µM SCH66336 under normoxic or hypoxic conditions. After incubation at 37 °C for 1 day, capillary tube formation was assessed as described elsewhere (23). Morphologic changes in the cells were assessed under a microscope and photographed at x40 magnification. Tube formation was scored; a three-branch-point event was scored as one tube (25). The experiment was repeated three times, each with similar results.
Immunoblot Assays
Whole-cell lysates were prepared in lysis buffer from 106 cells as described elsewhere (16). Equivalent amounts of protein (3080 µg) were resolved by SDSpolyacrylamide electrophoresis in 7.5%12% gels (80 V for 20 minutes and 100 V for 1 hour) and transferred by electroblotting overnight at 20 V to a nitrocellulose membrane. After nonspecific binding to the blot was blocked in Tris-buffered saline (TBS) containing 0.05% Tween 20 (TBST) and 5% nonfat powdered milk, the blot was incubated with primary antibody at the appropriate dilution in TBS5% nonfat milk at 4° C for 16 hours. The membrane was then washed multiple times with TBST and incubated with the appropriate horseradish peroxidaseconjugated secondary antibody for 1 hour at room temperature. The proteinantibody complexes were detected by using the enhanced chemiluminescence kit (Amersham, Arlington Heights, IL), according to the manufacturer's recommended protocol. To identify HIF-1 on these blots, 80 µg of protein was analyzed with a monoclonal antibody against HIF-1
(BD-Transduction Laboratories, Lexington, KY; 1 : 500 dilution), as described elsewhere (24). We used 30 µg of protein for other western blot analyses with mouse monoclonal antibodies against phosphorylated p44/42MAPK (pp44/42 MAPK; Thr202/Tyr204; 1 : 500 dilution) or HIF-1
(H1
234; 1 : 1000 dilution) (Novus Biologicals); rabbit polyclonal antibodies against phosphorylated Akt (Ser473; 1 : 1000 dilution), phosphorylated glycogen synthase kinase 3
(GSK-3
; 1 : 1000 dilution), GSK-3
, and VHL antibodies (1 : 1000 dilution) (Cell Signaling Technology, Beverly, MA); goat polyclonal antibodies against p44/42 MAPK (1 : 1000 dilution), rabbit polyclonal anti-Akt, -HA, -MEK1/2, and -
-actin (1 : 4000 dilution) antibodies (Santa Cruz Biotechnology, Santa Cruz, CA); rabbit polyclonal anti-HSP90 (1 : 5000 dilution) (Stressgen, Victoria, British Columbia, Canada); rabbit antimouse immunoglobulin G (IgG)horseradish peroxidase conjugate (1 : 2000 dilution; DAKO, Carpinteria, CA); and donkey antirabbit IgGhorseradish peroxidase conjugate (1 : 2000 dilution) and rabbit antigoat IgGhorseradish peroxidase conjugate (1 : 2000 dilution; both from Amersham Pharmacia Biotech, Arlington Heights, IL).
RTPCR Assay
Total RNA was isolated from cells by using the Trizol reagent (Invitrogen). cDNA was synthesized from 1 µg of total RNA as a template in a 50-µL reaction mixture by using TaqMan reverse transcription reagents, according to the manufacturer's protocol (Applied Biosystems, Foster City, CA). The reaction was incubated at 25 °C for 10 minutes and at 48 °C for 30 minutes and then inactivated at 95 °C for 5 minutes. After inactivation, the cDNA was stored at 20 °C until use. RTPCR was performed by coamplification of the genes with a reference gene (18S ribosomal RNA) by use of the cDNA template and corresponding gene-specific primer sets. The primer sequences were as follows: (sense) 5'-GGGAGAAAATCAAGTCGTGC-3' and (antisense) 5'-AGCAAGGAGGGCCTCTGATG-3' for HIF-1; (sense) 5'-CCATGAACTTTCTGCTGTCTT-3' and (antisense) 5'-ATCGCATCAGGGGCACACAG-3' for VEGF; (sense) 5'-GGTGAAGGTCGGTGTGAACGGATTT-3' and (antisense) 5'-AATGCCAAAGTTGTCATGGATGACC-3' for GAPDH. To avoid amplification of genomic DNA, we chose the primers from different exons. PCR was carried out in a total volume of 25 µL containing 1 µL of cDNA solution, 0.2 µM of sense primers, and 0.2 µM of antisense primers. The RTPCR exponential phase was determined after 2833 cycles to allow quantitative comparisons among the cDNAs developed from identical reactions. The thermocycler conditions used for amplification were 94 °C for 6 minutes (hot start) and then cycles of 94 °C for 45 seconds, 5660 °C for 45 seconds, and 72 °C for 1 minute. The control PCR was performed for 26 or 27 cycles with 0.5 µL of cDNA solution to allow quantitative comparisons among the cDNAs developed from identical reactions with primers for GAPDH. Amplified products (8 µL) were resolved on 2% agarose gels, stained with ethidium bromide, visualized with a transilluminator, and photographed.
Immunoprecipitation
Whole-cell lysates were prepared in lysis buffer (50 mM Tris, 150 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 5% glycerol, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor mixture [Roche diagnostics, Mannheim, Germany], pH 7.5), followed immediately by three 15-second periods of vortex mixing. After centrifugation (15 000g for 30 minutes at 4 °C), supernatants were transferred to fresh tubes. Supernatants (1 mg of protein each) were mixed with 1 µg of anti-HIF-1 antibody (Santa Cruz Biotechnology) and incubated at 4 °C overnight. Thereafter, 50 µL of protein ASepharose beads (Amersham Pharmacia Biotech AB, Uppsala, Sweden) was added, and the mixture was incubated at 4 °C for 4 hours. Beads were washed three times with the lysis buffer and two times with 1x phosphate-buffered saline, boiled in Laemmli loading buffer, and separated by SDSpolyacrylamide electrophoresis in 8% gels. HIF-1
(BD-Transduction Laboratories, Lexington, KY), Hsp90, and ubiquitin were assessed by immunoblot analysis with corresponding antibodies.
In Vivo Tumor Model and Immunohistochemical Staining
Sublingual injections for implantation of orthotopic tumors were performed as described elsewhere (26). All animal procedures were performed in accordance with a protocol approved by the M. D. Anderson institutional Animal Care and Usage Committee. We injected 2 x 106 UMSCC38 cells into the lateral tongue of anesthetized 6-week-old female nude mice (n = 5 per group). One week after tumor cell injection, when tumors started to develop, drug treatment was started. SCH66336 (40 mg/kg of body weight) or 20% hydroxyl-propyl-betacyclodexatrin control vehicle was given orally twice a day for 3 weeks. Two and 4 weeks after tumor cell injection, tumor size and body weight were measured; thereafter, the mouse food was replaced by commercially available soft food (transgenic mice dough; Bio-serv, Frenchtown, NJ) that the mice could swallow even when the oral cavity was blocked by tumor. Four weeks after tumor cell injection, the mice were humanely killed by exposure to CO2. Tumor growth was assessed by measuring tumor size in two dimensions and calculating tumor volume as described elsewhere (27). After each mouse was killed, its tongue was removed and divided into two parts.
One part of the tongue was fixed, embedded in paraffin, and sectioned for VEGF and HIF-1 staining. The 5-µm tumor tissue sections were deparaffinized through a series of xylene baths and rehydrated through a series of graded ethanol baths. The sections were then immersed in methanol containing 0.3% hydrogen peroxidase for 20 minutes to block endogenous peroxidase activity and incubated in 2.5% blocking serum to reduce nonspecific binding. Sections were incubated overnight at 4 °C with primary antibody against VEGF (Santa Cruz Biotechnology; 1 : 200 dilution) or HIF-1
(Santa Cruz Biotechnology; 1 : 100 dilution) and then processed for avidinbiotin immunohistochemistry according to the manufacturer's recommendations (Vector Laboratories, Burlingame, CA). Diaminobenzidine was used as a chromogen, and commercial hematoxylin was used for counterstaining. The other part of tongue was frozen for CD31 staining; 20-µm frozen sections of tumor tissues were stained with anti-CD31 antibody (1 : 100 dilution; BD-Pharmingen, San Diego, CA), and then the antibody was detected by Cy3-conjugated secondary antibody as previously described (28).
Statistical Analysis
Data are expressed as the means and 95% confidence intervals (CIs) from triplicate samples, calculated with Microsoft Excel software (version 5.0; Microsoft Corporation, Seattle, WA). The Wilcoxon rank-sum test in the statistical SPSS statistical program (SPSS version 10; SPSS, Chicago, IL) was used to determine the statistical significance of antitumorigenic and antiangiogenic effects of SCH66336. Cell proliferation data were analyzed with a Student's t test. The null hypothesis that there was no difference in the cell proliferation between control and treatment groups was rejected at the probability (P) of less than .05. All statistical tests were two-sided.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We investigated whether the farnesyltransferase inhibitor SCH66336 had antiangiogenic activity on aerodigestive tract cancer cells, including NSCLC and HNSCC cells. The angiogenic process consists of several steps that include degradation of the basement membrane by endothelial cells, migration to the extravascular space, proliferation, and synthesis of a new basement membrane (29). We first performed the ex vivo chick aortic arch ring assay to determine the effects of SCH66336 on the ability of aerodigestive tract cancer cells to promote growth and migration of endothelial cells in three-dimensional cultures. The cell sprouting was evaluated by scoring angiogenic activity on a scale of 04. Conditioned medium from untreated control H1299 cells stimulated statistically significantly more endothelial cell sprouting (mean = 3, 95% CI = 2.2 to 3.8) than EBM (mean = 1, 95% CI = 0.2 to 1.8) (P = .04) (Fig. 1, A). However, conditioned medium from SCH66336-treated cells stimulated less endothelial cell sprouting (mean = 0.5, 95% CI = 0.1 to 0.9) than conditioned medium from untreated control cells (P = .03).
|
Finally, because tumor angiogenesis is induced by angiogenic growth factors that are secreted from hypoxia- or IGF-stimulated cancer cells and then bind to their corresponding receptors expressed on endothelial cells to stimulate endothelial cell proliferation (30), we investigated whether conditioned medium from SCH66336-treated H1299 cells altered HUVEC proliferation. We found that addition of conditioned medium from hypoxic, normoxic IGF-stimulated, or unstimulated normoxic H1299 cells statistically significantly increased proliferation of HUVECs, whereas addition of conditioned medium from SCH66336-treated cells statistically significantly decreased HUVEC proliferation under hypoxic (73.2% of control growth stimulation, 95% CI = 68.2% to 78.2%; P = .004) or normoxic (67.1% of control growth stimulation, 95% CI = 63.0% to 71.1%; P = .002) conditions (Fig. 1, C). HUVECs incubated with conditioned medium from hypoxic, normoxic IGFstimulated, or unstimulated normoxic UMSCC38 cells had comparable patterns of decreased cell proliferation (data not shown). Thus, SCH66336 appears to inhibit hypoxia- or growth factorstimulated and constitutive secretion of angiogenic growth factors from aerodigestive tract cancer cells.
Expression of HIF-1 and VEGF by SCH66336-treated Cells
Because VEGF plays an important role in angiogenesis and because its expression is regulated largely by the transcription factor HIF-1, we investigated whether SCH66336 treatment alters the expression, and thus the secretion, of HIF-1
and VEGF in aerodigestive tract cancer cells. To determine whether HIF-1
is involved in the regulation of VEGF in H1299 cells, we transfected these cells with an siRNA targeting HIF-1
, to inhibit the expression of HIF-1
, or with a control scrambled siRNA and measured VEGF levels in corresponding conditioned media. The basal level of HIF-1
protein in untransfected H1299 cells was very low but increased markedly after cells were incubated under hypoxic conditions for 4 hours (Fig. 2, A). Levels of HIF-1
and VEGF proteins in H1299 cells transfected with HIF-1
siRNA were lower in normoxic and hypoxic conditions than cells transfected with scrambled siRNA. As expected, HIF-1
protein expression was unchanged in these cells. Thus, the expression of HIF-1
and VEGF appear to be associated in H1299 cells.
|
We then investigated whether SCH66336 treatment could alter the level of HIF-1 protein in H1299 cells under hypoxic, normoxic and IGF-stimulated, or normoxic and unstimulated conditions. Hypoxic conditions or IGF treatment increased the expression of HIF-1
protein in H1299 cells, compared with that in cells under normoxic conditions, and this increased expression was reduced by SCH66336 treatment in a time- and dose-dependent manner (Fig. 2, D). In addition, the level of HIF-1
protein in unstimulated H1299 cells was also reduced by SCH66336 treatment, but the level of HIF-1
protein was not altered by SCH66336 treatment under any condition tested. Another farnesyltransferase inhibitor, FTI-277, also decreased the level of HIF-1
protein in hypoxic, normoxic IGF-stimulated, and normoxic unstimulated H1299 cells (Fig. 2, E). In addition, patterns of decreased HIF-1
protein expression, which were similar to those in H1299 cells, were observed in UMSCC38 HNSCC cells treated with SCH66336 or FTI-277 under hypoxic, normoxic IGF-stimulated, and normoxic unstimulated conditions (Fig. 2, F). Thus, inhibition of HIF-1
protein in aerodigestive tract cancer cells appears to be a generic response to farnesyltransferase inhibitors.
We next tested whether the SCH66336-mediated decreased HIF-1 protein expression was associated with VEGF expression in hypoxic, normoxic IGF-stimulated, and normoxic unstimulated H1299 cells. Both VEGF mRNA expression in the SCH66336-treated cells and VEGF protein secreted in the conditioned medium decreased under all conditions tested, whereas GAPDH mRNA expression was not affected (Fig. 2, G). Thus, suppression of HIF-1
expression by SCH66336 appears to contribute to the inhibition of hypoxia- or IGF-stimulated, or constitutive VEGF production.
Because HIF-1 has recently been shown to have an important role in endothelial-cell survival (33), we investigated whether SCH66336 treatment would alter the expression of HIF-1
in HUVECs. Pretreatment of HUVECs with 5 µM SCH66336 inhibited the expression of HIF-1
protein and VEGF mRNA under hypoxic, normoxic IGF-stimulated, and normoxic unstimulated conditions, similar to the patterns previously observed (Fig. 3, A). We also examined whether SCH66336 treatment would alter HUVEC capillary tube formation and cell proliferation. For the capillary tube formation assay, HUVECs were untreated or treated with 5 µM SCH66336 for 24 hours under hypoxic or normoxic conditions, and 5 x 104 untreated or treated cells were cultured on a Trans-well chamber coated with a thin layer of Matrigel. In control medium, capillary tube formation was observed after 6 hours of incubation and was almost completed at 24 hours (Fig. 3, B); however, in medium containing 5 µM SCH66336 under hypoxic (mean = 16.4% of control capillary tube formation, 95% CI = 9.4% to 23.5%, P<.001) or normoxic (mean = 6.4% of control capillary tube formation, 95% CI = 3.0% to 9.7%, P<.001) conditions, HUVECs were statistically significantly less able to differentiate into capillary tube-like structures. For the cell proliferation assay, HUVECs were treated with 5 µM SCH66336 for 3 days under hypoxic or normoxic conditions, and cell proliferation was assessed. Proliferation of SCH66336-treated cells was statistically significantly lower under hypoxic (1.0 µM SCH66336, 83.2%, 95% CI = 80.3% to 86.1%, P<.001; 5 µM SCH66336, 66.3%, 95% CI = 63.5% to 69.1%, P<.001) and normoxic (1.0 µM SCH66336, 69.6%, 95% CI = 65.8% to 73.4%, P<.001; 5 µM SCH66336, 52.7%, 95% CI = 50.2% to 55.2%, P<.001) conditions than that of untreated cells (Fig. 3, C). These data suggest that SCH66336 acts directly on endothelial cells to inhibit the angiogenic-associated processes of tube formation and cell proliferation.
|
To determine whether SCH66336 inhibits HIF-1 protein and VEGF expression in vivo and whether inhibition of these proteins affects tumor angiogenesis and tumor growth in vivo, we established HNSCC orthotopic tongue tumors in nude mice and treated the mice with SCH66336. Three weeks of oral treatment with SCH66336 (40 mg/kg) statistically significantly suppressed tongue tumor growth compared with untreated tumors (P = .02). On day 28 of cell injection, the average tumor volume among untreated control mice had increased to 336.4% of the pretreatment volume, whereas that among SCH66336-treated mice was 123.8% of the pretreatment volume (difference in means = 212.6, 95% CI for difference = 150.7% to 274.4%; P = .02) (Fig. 4, A, left panel). In contrast, the average body weight of SCH66336-treated mice was not reduced during the treatment (Fig. 4, A, middle panel), indicating that side effects of SCH66336 are minimal.
|
SCH66336 and IGF-Iinduced HIF-1 Protein Synthesis
We next investigated the mechanism through which SCH66336 reduces the expression of HIF-1. Because HIF-1
protein expression is very weak in normoxic unstimulated cells, we used hypoxic and normoxic IGF-stimulated H1299 cells for these studies. H1299 cells under hypoxic and normoxic IGF-stimulated conditions were treated with SCH66336, and then total RNA was isolated and subjected to RTPCR. Untreated cells served as the control group. SCH66336 treatment did not measurably alter HIF-1
mRNA levels in the hypoxic and normoxic IGF-stimulated cells (Fig. 5, A), indicating that SCH66336 affects the level of HIF-1
at the posttranscriptional level, possibly by decreasing the rate of degradation and/or increasing the rate of synthesis (14).
|
Because HIF-1 protein is degraded mainly through the ubiquitinproteasome pathway, we investigated whether SCH66336-induced reduced HIF-1
protein level is dependent on proteasomal degradation by incubating SCH66336-treated H1299 cells with proteasome inhibitors and measuring the level of HIF-1
protein in such cells. Pretreatment for 8 hours with various proteasome inhibitors, including 10 µM MG132 or 10 µM ALLN, prevented the SCH66336-mediated decrease in the level of HIF-1
protein under hypoxic or IGF-Istimulated conditions (Fig. 5, C). Because the polyubiquitin chain, which serves as a recognition signal for targeting the proteasome (34), is added to most proteins degraded in the proteasome, we examined polyubiquitination of HIF-1
and found that treatment of cells with a proteasome inhibitor, alone or in combination with SCH66336, resulted in the formation of polyubiquitinated, higher-molecular-weight forms of HIF-1
(Fig. 5, D). Thus, SCH66336 appears to interfere with HIF-1
protein accumulation by modifying a proteasome-dependent degradation pathway under hypoxic and normoxic IGF-stimulated conditions.
Role of VHL in SCH66336-mediated Degradation of HIF-1
We next investigated the role of VHL in the mechanism of SCH66336-mediated reduced HIF-1 expression in H1299 cells, because HIF-1
is constitutively stabilized in normoxic tumors and in cell lines that are VHL-null or that express a nonfunctional mutant form of VHL (35) and because VHL-inactivated tumors are highly vascularized and overproduce VEGF (36). We assessed the levels of VHL in hypoxic or normoxic IGF-stimulated or normoxic unstimulated SCH66336-pretreated H1299 cells and found that the expression of VHL protein in these cells was not changed by treatment with 5 µM SCH66336 (Fig. 6, A). We also examined whether inhibition of VHL expression with a VHL siRNA abrogates the effects of SCH66336 on HIF-1
expression by use of H1299 cells that were untransfected or transfected with a VHL or a control scrambled siRNA. We confirmed that VHL expression decreased in VHL siRNA-transfected H1299 cells (data not shown) and then measured HIF-1
protein levels in cells under various conditions. HIF-1
protein expression was higher in normoxic IGF-stimulated or unstimulated VHL siRNA-transfected H1299 cells than in control scrambled siRNAtransfected cells (Fig. 6, B). However, use of VHL siRNA to inhibit VHL expression did not abrogate the effects of SCH66336 on HIF-1
expression in H1299 cells under any condition tested. Thus, SCH66336 appears to reduce the level of HIF-1
by acting through VHL-independent pathways.
|
Because PI3KAkt and p44/42 MAPK pathways have been implicated in synthesis and stabilization of HIF-1 protein [for review, see Semenza (14)] and because SCH66336 can inhibit these pathways, we first investigated whether the PI3KAkt and p44/42 MAPK pathways are involved in SCH66336-mediated decreased HIF-1
expression in H1299 cells. SCH66336 treatment decreased the levels of phosphorylated Akt (Ser-473) and phosphorylated p44/42 MAPK in hypoxic and normoxic IGF-stimulated H1299 cells, whereas the level of phosphorylated Akt was mildly decreased and the level of phosphorylated p44/42 MAPK was not affected by SCH66336 treatment in normoxic unstimulated H1299 cells (Fig. 6, C). Unphosphorylated Akt and p44/42 MAPK remained unchanged in the cells under every condition examined. Thus, expression of Akt and p44/42 MAPK does not appear to be affected by SCH66336 treatment.
Second, we explored whether the PI3KAkt and p44/42 MAPK signaling pathways are involved in SCH66336-mediated decreased HIF-1 protein levels. In this experiment, we infected H1299 cells with a control adenoviral vector (EV), an adenovirus expressing HA-MyrAkt (Ad-HA-MyrAkt) to generate constitutively active Akt, or an adenovirus expressing MEK1 (Ad-MEK1) to generate constitutively active MEK1. The induced expression of HA-MyrAkt and MEK1 and the constitutive activity of these proteins were confirmed by western blot analysis with antibodies against HA, MEK1, phosphorylated GSK-3
, an Akt downstream effector, and p44/42MAPK, as previously described (19) (Fig. 6, DG). We next determined whether infection by Ad-HA-MyrAkt or Ad-MEK1 could protect HIF-1
expression from SCH66336-mediated degradation. Basal levels of HIF-1
protein levels were increased by Ad-HA-MyrAkt or Ad-MEK1 infection in hypoxic (Fig. 6, D, F), normoxic IGF-stimulated (Fig. 6, E, G), or normoxic unstimulated (Fig. 6, H) H1299 cells. However, treatment with SCH66336 mediated a decrease in the level of HIF-1
protein in these cells that was not restored when HA-MyrAkt or MEK1 were overexpressed, suggesting that neither the PI3KAkt pathway nor the MAPK pathway plays a major role in protecting HIF-1
protein from SCH66336-mediated degradation in H1299 cells.
Hsp90 and Destabilization of HIF-1 Induced by SCH66336 Under Normoxic and Hypoxic Conditions
Because the protein chaperone Hsp90 plays a pivotal role in mediating the proper folding and subsequent activation of its many client proteins, including HIF-1 (37), we investigated the role of Hsp90 in HIF-1
protein expression under hypoxic, normoxic IGF-stimulated, or normoxic unstimulated conditions in H1299 cells, by examining whether overexpression of Hsp90 would protect H1299 cells from the SCH66336-induced degradation of HIF-1
. We introduced Hsp90 into H1299 cells by infection with an adenoviral vector containing HA-tagged Hsp90 under the control of the cytomegalovirus promoter (i.e., Ad-HA-Hsp90). Induction of Hsp90 protein expression in the cells infected with Ad-HA-Hsp90 was confirmed by the appearance of the HA band on a western blot probed with an anti-HA antibody (Fig. 7, A). Under hypoxic or normoxic IGF-stimulated conditions, cells infected with Ad-HA-Hsp90 were completely rescued from the HIF-1
inhibiting effect of SCH66336, unlike cells infected with the control vector (Fig. 7, A). However, the SCH66336-mediated decrease in HIF-1
protein level was not restored by overexpression of Hsp90 in normoxic unstimulated cells. Thus, Hsp90 activity appears to be required for the accumulation of HIF-1
protein induced by hypoxia or IGF-I, but SCH66336 appears to modify the constitutive expression of HIF-1
protein under normoxic conditions through an Hsp90-independent pathway.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Angiogenesis has a critical role in primary tumor growth and metastasis (39,40). A principal mediator of tumor angiogenesis is VEGF, and a major transcriptional activator of the VEGF gene is HIF-1 (9). An increasing body of evidence indicates that oncogenes, growth factors, and hypoxia regulate VEGF expression by elevating the HIF-1
translation rate and stability via activation of MAPK or PI3KAkt pathways (41,42). Moreover, Hsp90 associates with HIF-1
and increases its stability and function (14,15). Consequently, agents that block PI3KAkt and MAPK signaling pathways and/or Hsp90 function may be candidates to inhibit tumor angiogenesis via decreasing HIF-1
and VEGF expression.
The antiangiogenic actions of SCH66336 in aerodigestive tract cancers could have been the result of blocking farnesylation of RAS or inducing geranylgeranylation of RhoB (43), but H1299 (16,44,45) and UMSCC38 cells used in this study have no ras mutations. In addition, antiangiogenic activities of SCH66336 were unchanged when H-Ras or RhoB expression was knocked down by transfection with H-Ras or RhoB siRNA (unpublished data), indicating the presence of other as yet unidentified targeted proteins.
The farnesyltransferase inhibitor SCH66336 decreased the half-life of the HIF-1 protein by inducing ubiquitin-mediated protein degradation, resulting in the decreased expression of HIF-1
and VEGF in NSCLC and HNSCC cell lines and in HUVECs. Given the importance of HIF-1
and VEGF to survival of endothelial cells has recently been demonstrated (46,47), the SCH66336-mediated loss of HIF-1
by in these cells may disrupt HIF-1
driven VEGF-induced autocrine and paracrine loops, inhibiting endothelial cell proliferation and suppressing tumor angiogenesis.
We further investigated the mechanism of SCH66336-mediated posttranslational degradation of HIF-1. We first hypothesized that SCH66336-mediated HIF-1
degradation is caused, at least in part, by decreased MAPK and PI3KAkt activities because 1) MAPK and PI3KAkt pathways have critical roles in HIF-1
expression, 2) SCH66336 inhibited activation of MAPK and Akt in hypoxic and normoxic IGF-stimulated H1299 cells, and 3) expression of HIF-1
was increased in H1299 cells by constitutive activation of MAPK and Akt under both hypoxic and normoxic conditions. Overexpression of a constitutively active Akt or a constitutively active MEK1 failed, however, to overcome the SCH66336-mediated decrease in the level of HIF-1
protein, indicating that the action of SCH66336 on HIF-1
may be independent of its inhibitory effects on PI3KAkt and MAPK pathways. We also found that VHL, which has an important role in ubiquitin-mediated degradation of HIF-1
(35), is not implicated in the SCH66336-mediated decrease in HIF-1
protein level. Therefore, SCH66336 appears to affect the level of HIF-1
through mechanisms other than inactivation of MAPK, PI3KAkt, or VHL.
Because Hsp90 binds to HIF-1 and prevents its ubiquitination and proteasome-mediated degradation, independently of both oxygen concentration and VHL (15), Hsp90 was another candidate target of farnesyltransferase inhibitor function. Geldanomycin, which specifically binds in the amino-terminal ATP-binding site of Hsp90 and inhibits Hsp90-dependent ATPase activity, induces destabilization and degradation of HIF-1
(15,48). We found that overexpression of Hsp90 by infection by an adenoviral vector completely blocked the SCH66336-mediated decrease in HIF-1
protein level in hypoxic and normoxic IGF-stimulated H1299 cells and that SCH66336 induced dissociation of HIF-1
from Hsp90 before HIF-1
protein levels decreased in these cells. Therefore, HIF-1
protein is probably protected by Hsp90 under hypoxic conditions. In addition, under normoxic conditions, most growth factorinduced HIF-1
is changed to a hydroxylated form, binds to VHL, and is degraded by the ubiquitin-mediated proteasome. The HIF-1
that remains bound to Hsp90, and is thus protected, could function as a transcription factor for VEGF (Fig. 8). Thus, Hsp90 appears to be required to chaperone growth factor- and hypoxia-induced HIF-1
protein under normoxic or hypoxic conditions. The role of Hsp90 in maintaining HIF-1
stability has been documented, insofar as Hsp90 inhibitors cause ubiquitination of HIF-1
, targeting the proteasome, and its degradation (15,4952). Therefore, SCH66336-mediated blockade of the interaction between Hsp90 and HIF-1
may be quite important in decreasing HIF-1
expression and VEGF gene transcription in normoxic IGF-induced and hypoxic cells.
|
We found that basal HIF-1 expression was stimulated in a cell typespecific manner. Under hypoxic conditions, H1299 cells expressed higher levels of HIF-1
than UMSCC 38 cells, whereas under normoxic, IGF-Istimulated conditions, UMSCC38 cells expressed higher levels of HIF-1
than H1299 cells, suggesting that differences in genetic background of cells contribute to the variable HIF-1
and VEGF expression. Moreover, levels of HIF-1
were not completely associated with VEGF production by cancer cells, and the level of HIF-1
alone cannot account for VEGF expression. In addition, the association between HIF-1
expression and cancer cells' stimulating effects on HUVEC proliferation was not strong. These collective findings indicated that regulation of HIF-1
may not be sufficient to explain antiangiogenic activities of SCH66336 and that the drug can influence other pathways involved in the angiogenic activities of cancer cells.
Overexpression of HIF-1 protein has been demonstrated in a variety of human cancers including aerodigestive cancers, in which HIF-1
protein overexpression is associated with poor prognosis (19,5661). Disruption of HIF-1
transcriptional activity has shown therapeutic effects in xenograft models of colon and breast cancers (8). SCH66336 suppressed HIF-1
protein levels at a concentration less than 5 µM, which is considerably below that achievable in vivo (about 8 µM) in mice given a single oral dose of SCH66336 at 25 mg/kg (62). Thus, these results provide an important new rationale for the use of farnesyltransferase inhibitors as an inhibitor of tumor angiogenesis in aerodigestive tract cancers, which depends in part on HIF-1 overexpression for tumor angiogenesis. Because farnesyltransferase inhibitors are not specific for HIF-1
, their inhibition of HIF-1
and reduction in VEGF levels could be circumstantial, and additional inhibitory pathways could be involved. Further investigations into the role of other VEGF-inducing transcription factors in HIF-1
regulation by SCH66336 (9) are required.
![]() |
NOTES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Supported by National Institutes of Health grants R01 CA100816-01 and R01 CA109520-01 (to H.-Y. Lee), American Cancer Society grant RSG-04-082-01-TBE 01 (to H.-Y. Lee), M. D. Anderson Cancer Center Spore Grant in Head and Neck Cancer, P50 CA 97007-01 (to W.K. Hong), U.S. Department of Defense grant DAMD17-01-1-0689 (to W.K. Hong), and NFCR grant LF01-065-1 (to W.K. Hong); W.K. Hong is an American Cancer Society clinical research professor.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
(1) Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:48590.[CrossRef][ISI][Medline]
(2) Coello MC, Luketich JD, Litle VR, Godfrey TE. Prognostic significance of micrometastasis in non-small-cell lung cancer. Clin Lung Cancer 2004;5:21425.[Medline]
(3) Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998;49:40724.[CrossRef][ISI][Medline]
(4) Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795803.[CrossRef][ISI][Medline]
(5) Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc 2000;5:2433.[CrossRef][ISI][Medline]
(6) Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001;12:3639.
(7) Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002;277:3820511.
(8) Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996;271:177718.
(9) Harris AL. Hypoxiaa key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:3847.[CrossRef][ISI][Medline]
(10) Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:46872.
(11) Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:4648.
(12) Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:15415.
(13) Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002;277:2797581.
(14) Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:72132.[CrossRef][ISI][Medline]
(15) Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 2002;277:2993644.
(16) Lee HY, Moon H, Chun KH, Chang YS, Hassan K, Ji L, et al. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in nonsmall-cell lung cancer cells. J Natl Cancer Inst 2004;96:153648.
(17) Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:5770.[CrossRef][ISI][Medline]
(18) Chun KH, Lee HY, Hassan K, Khuri F, Hong WK, Lotan R. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res 2003;63:4796800.
(19) Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 2000;19:634150.
(20) Chun KH, Kosmeder JW 2nd, Sun S, Pezzuto JM, Lotan R, Hong WK, et al. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 2003;95:291302.
(21) Fontana J, Fulton D, Chen Y, Fairchild TA, McCabe TJ, Fujita N, et al. Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ Res 2002;90:86673.
(22) Gibbs JB, Graham SL, Hartman GD, Koblan KS, Kohl NE, Omer CA, et al. Farnesyltransferase inhibitors versus Ras inhibitors. Curr Opin Chem Biol 1997;1:197203.[CrossRef][ISI][Medline]
(23) Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001;7:43743.[CrossRef][ISI][Medline]
(24) Malinda KM, Nomizu M, Chung M, Delgado M, Kuratomi Y, Yamada Y, et al. Identification of laminin alpha1 and beta1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting. FASEB J 1999;13:5362.
(25) Reimer CL, Agata N, Tammam JG, Bamberg M, Dickerson WM, Kamphaus GD, et al. Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. Cancer Res 2002;62:78995.
(26) Myers JN, Holsinger FC, Jasser SA, Bekele BN, Fidler IJ. An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin Cancer Res 2002;8:2938.
(27) Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, Hong WK, et al. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res 2002;62:35307.
(28) Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld G, Gunn MD, et al. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J 2002;21:150513.
(29) Ponce ML, Nomizu M, Delgado MC, Kuratomi Y, Hoffman MP, Powell S, et al. Identification of endothelial cell binding sites on the laminin gamma 1 chain. Circ Res 1999;84:68894.
(30) Shepherd FA. Angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2001;34(Suppl 3):S819.
(31) Rak J, Mitsuhashi Y, Sheehan C, Tamir A, Viloria-Petit A, Filmus J, et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 2000;60:4908.
(32) Lim JH, Lee ES, You HJ, Lee JW, Park JW, Chun YS. Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene 2004;23:942731.[CrossRef][ISI][Medline]
(33) Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004;6:48595.[CrossRef][ISI][Medline]
(34) Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998;17:715160.
(35) Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001;61:521522.
(36) Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A 1997;94:87616.
(37) Caplan AJ. Hsp90's secrets unfold: new insights from structural and functional studies. Trends Cell Biol 1999;9:2628.[CrossRef][ISI][Medline]
(38) Minet E, Mottet D, Michel G, Roland I, Raes M, Remacle J, et al. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett 1999;460:2516.[CrossRef][ISI][Medline]
(39) Folkman J. Fighting cancer by attacking its blood supply. Sci Am 1996;275:1504.[ISI][Medline]
(40) Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:175763.
(41) Chan DA, Sutphin PD, Denko NC, Giaccia AJ. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. J Biol Chem 2002;277:401127.
(42) Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21:39954004.
(43) Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000;19:658493.[CrossRef][ISI][Medline]
(44) Chun KH, Lee HY, Hassan K, Khuri F, Hong WK, Lotan R. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res 2003;63:4796800.
(45) Mitsudomi T, Steinberg SM, Oie HK, Mulshine JL, Phelps R, Viallet J, et al. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991;51:49995002.[Abstract]
(46) Franklin SL, Ferry RJ Jr, Cohen P. Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. J Clin Endocrinol Metab 2003;88:9007.
(47) Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004;6:48595.[CrossRef][ISI][Medline]
(48) Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002;62:247882.
(49) Suzuki H, Tomida A, Tsuruo T. Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 2001;20:577988.[CrossRef][ISI][Medline]
(50) Katschinski DM, Le L, Heinrich D, Wagner KF, Hofer T, Schindler SG, et al. Heat induction of the unphosphorylated form of hypoxia-inducible factor-1alpha is dependent on heat shock protein-90 activity. J Biol Chem 2002;277:92627.
(51) Gradin K, McGuire J, Wenger RH, Kvietikova I, Whitelaw ML, Toftgard R, et al. Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. Mol Cell Biol 1996;16:522131.[Abstract]
(52) Kallio PJ, Okamoto K, O'Brien S, Carrero P, Makino Y, Tanaka H, et al. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J 1998;17:657386.
(53) Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 2004;40:221729.[CrossRef][ISI][Medline]
(54) Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Hohfeld J, et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 2001;3:936.[CrossRef][ISI][Medline]
(55) Melillo G, Taylor LS, Brooks A, Musso T, Cox GW, Varesio L. Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine. J Biol Chem 1997;272:1223643.
(56) Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001;85:88190.[CrossRef][ISI][Medline]
(57) Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002;8:18317.
(58) Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:46936.
(59) Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61:29116.
(60) Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, et al. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 2001;61:18302.
(61) Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000;6:133540.[CrossRef][ISI][Medline]
(62) Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 1998;58:494756.[Abstract]
Manuscript received October 20, 2004; revised June 28, 2005; accepted July 21, 2005.
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |